{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:17:52Z","timestamp":1791152272472,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":577,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Infection with hepatitis B virus (HBV) is the most common cause of liver disease worldwide. However, because the current interferon (IFN)-based treatments have toxic side effects and marginal efficacy, improved antivirals are essential. Here we report that unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODNs) from the HBV genome (HBV-CpG) induced robust expression of IFN-\u03b1 by plasmacytoid dendritic cells (pDCs) in a Toll-like receptor 9 (TLR9)-dependent manner. We also identified inhibitory guanosine-rich ODNs in the HBV genome (HBV-ODN) that are capable of inhibiting HBV-CpG-induced IFN-\u03b1 production. Furthermore, nanoparticles containing HBV-CpG, termed NP(HBV-CpG), reversed the HBV-ODN-mediated suppression of IFN-\u03b1 production and also exerted a strong immunostimulatory effect on lymphocytes. Our results suggest that NP(HBV-CpG) can enhance the immune response to hepatitis B surface antigen (HBsAg) and skew this response toward the Th1 pathway in mice immunized with rHBsAg and NP(HBV-CpG). Moreover, NP(HBV-CpG)-based therapy led to the efficient clearance of HBV and induced an anti-HBsAg response in HBV carrier mice.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>: Endogenous HBV-CpG ODNs from the HBV genome induce IFN-\u03b1 production so that nanoparticle-encapsulated HBV-CpG may act as an HBsAg vaccine adjuvant and may also represent a potent therapeutic agent for the treatment of chronic HBV infection. (Hepatology 2014;59:385\u2013394)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26654","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T16:43:30Z","timestamp":1375375410000},"page":"385-394","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":48,"title":["Nanoparticles Encapsulating Hepatitis B Virus Cytosine-Phosphate-Guanosine Induce Therapeutic Immunity against HBV Infection"],"prefix":"10.1097","volume":"59","author":[{"given":"Shujuan","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20250207","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(03)15108-2","article-title":"Viral hepatitis B.","volume":"362","author":"Lai","year":"2003","journal-title":"Lancet"},{"key":"R2-8-20250207","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection.","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"R3-8-20250207","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1073\/pnas.161293498","article-title":"Human TLR9 confers responsiveness to bacterial DNA via speciesspecific CpG motif recognition.","volume":"98","author":"Bauer","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-8-20250207","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2358","article-title":"Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases.","volume":"8","author":"Gilliet","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"R5-8-20250207","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.167.7.3555","article-title":"Cutting edge: role of Tolllike receptor 9 in CpG DNAinduced activation of human cells.","volume":"167","author":"Takeshita","year":"2001","journal-title":"J Immunol"},{"key":"R6-8-20250207","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1369-5274(02)00287-4","article-title":"Interactions between bacterial CpGDNA and TLR9 bridge innate and adaptive immunity.","volume":"5","author":"Wagner","year":"2002","journal-title":"Curr Opin Microbiol"},{"key":"R7-8-20250207","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Tolllike receptor 9 activation.","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R8-8-20250207","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to EngerixB HBV vaccine in healthy adults: a doubleblind phase III study.","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"key":"R9-8-20250207","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.21773","article-title":"Phase 1B, randomized, doubleblind, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus.","volume":"46","author":"McHutchison","year":"2007","journal-title":"Hepatology"},{"key":"R10-8-20250207","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/135965350901400115","article-title":"Inhibitory effect of the combination of CpGinduced cytokines with lamivudine against hepatitis B virus replication in vitro.","volume":"14","author":"Vincent","year":"2009","journal-title":"Antivir Ther"},{"key":"R11-8-20250207","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.","volume":"239","author":"Houghton","year":"2011","journal-title":"Immunol Rev"},{"key":"R12-8-20250207","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/nat.2012.0340","article-title":"CpG still rocks! Update on an accidental drug.","volume":"22","author":"Krieg","year":"2012","journal-title":"Nucleic Acid Ther"},{"key":"R13-8-20250207","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nm987","article-title":"Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.","volume":"10","author":"Heikenwalder","year":"2004","journal-title":"Nat Med"},{"key":"R14-8-20250207","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4049\/jimmunol.176.1.248","article-title":"Virus or TLR agonists induce TRAILmediated cytotoxic activity of plasmacytoid dendritic cells.","volume":"176","author":"Chaperot","year":"2006","journal-title":"J Immunol"},{"key":"R15-8-20250207","doi-asserted-by":"crossref","first-page":"17862","DOI":"10.1073\/pnas.0608578103","article-title":"An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection.","volume":"103","author":"Huang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-8-20250207","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.23.021704.115633","article-title":"IPC: professional type 1 interferonproducing cells and plasmacytoid dendritic cell precursors.","volume":"23","author":"Liu","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"R17-8-20250207","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/ni1141","article-title":"Plasmacytoid dendritic cells in immunity.","volume":"5","author":"Colonna","year":"2004","journal-title":"Nat Immunol"},{"key":"R18-8-20250207","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.intimp.2011.02.023","article-title":"Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.","volume":"11","author":"Ashman","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"R19-8-20250207","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.171.3.1393","article-title":"Repetitive elements in mammalian telomeres suppress bacterial DNAinduced immune activation.","volume":"171","author":"Gursel","year":"2003","journal-title":"J Immunol"},{"key":"R20-8-20250207","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1099\/vir.0.81920-0","article-title":"The immune response during hepatitis B virus infection.","volume":"87","author":"Bertoletti","year":"2006","journal-title":"J Gen Virol"},{"key":"R21-8-20250207","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ni1028","article-title":"TLR9 signals after translocating from the ER to CpG DNA in the lysosome.","volume":"5","author":"Latz","year":"2004","journal-title":"Nat Immunol"},{"key":"R22-8-20250207","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jconrel.2011.07.035","article-title":"Systemic delivery of siRNA with cationic lipid assisted PEGPLA nanoparticles for cancer therapy.","volume":"156","author":"Yang","year":"2011","journal-title":"J Control Release"},{"key":"R23-8-20250207","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00281-012-0335-7","article-title":"Experimental models and therapeutic approaches for HBV.","volume":"35","author":"Dandri","year":"2013","journal-title":"Semin Immunopathol"},{"key":"R24-8-20250207","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10875-004-6249-y","article-title":"Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans.","volume":"24","author":"Duan","year":"2004","journal-title":"J Clin Immunol"},{"key":"R25-8-20250207","doi-asserted-by":"crossref","first-page":"e26315","DOI":"10.1371\/journal.pone.0026315","article-title":"Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells.","volume":"6","author":"Vincent","year":"2011","journal-title":"PLoS One"},{"key":"R26-8-20250207","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.addr.2008.12.012","article-title":"CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.","volume":"61","author":"Klinman","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"R28-8-20250207","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/vim.2010.0116","article-title":"Plasmids enriched with CpG motifs activate human peripheral blood mononuclear cells in vitro and enhance th1 immune responses to hepatitis B surface antigen in mice.","volume":"24","author":"Chen","year":"2011","journal-title":"Viral Immunol"},{"key":"R29-8-20250207","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1021\/mp2003835","article-title":"Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin Oliposomes promotes a Th1type response and CTL activity.","volume":"9","author":"Andrews","year":"2012","journal-title":"Mol Pharm"},{"key":"R30-8-20250207","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.intimp.2010.12.005","article-title":"CpG oligodeoxynucleotideadjuvanted fusion peptide derived from HBcAg epitope and HIVTat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase.","volume":"11","author":"Wang","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"R31-8-20250207","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1042\/CS20120169","article-title":"Hepatitis B virus: from immunobiology to immunotherapy.","volume":"124","author":"Grimm","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"R32-8-20250207","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1084\/jem.20061660","article-title":"Plasmacytoid dendritic cells prime IL10producing T regulatory cells by inducible costimulator ligand.","volume":"204","author":"Ito","year":"2007","journal-title":"J Exp Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26654","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201402000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:54:14Z","timestamp":1738947254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201402000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26654","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}